J&J lowered its revenue and earnings expectations for 2022

J&J lowered its revenue and earnings expectations for 2022

April 20, 2022: On Tuesday, Johnson & Johnson ( J&J ) lowered its full-year sales and earnings outlook and stopped providing Covid-19 vaccine revenue guidance because of a global supply surplus and demand uncertainty.

J&J forecasts sales of $94.8 billion to $95.8 billion, about $1 billion less than the guidance provided in January. The company lowered its adjusted earnings per share by 25 cents to $10.15 and $10.35 for the whole year, from the last forecast of $10.40 to $10.60.

J&J reported first-quarter sales of $23.4 billion, slightly missing Wall Street expectations but growing 5% over the same quarter last year. The company posted earnings of 2.67 cents per share, beating expectations and increasing 3.1% over the same period of 2021. J&J reported a net income of $5.15 billion, a nearly 17% decrease over the first quarter of 2021.

CFO Joe Wolk said Tuesday that developing nations have limited capacity in terms of refrigeration and getting shots in arms, which has created a backlog of vaccines. The company sold $457 million of its Covid vaccine globally. When asked about no longer providing a sales outlook for the photos, Wolk said it was unusual to guide a specific product, to begin with.

“We did it last year because we understood the Street had an expectation or at least an excitement around understanding how vaccine sales might play out, but it was never material,” Wolk told CNBC’s Meg Tirrell on “Squawk Box,” noting the vaccine is not for profit and doesn’t impact the company’s bottom line. He said Covid vaccine sales met J&J’s internal expectations.

J&J reported $12.87 billion in pharmaceutical sales, a raise of 6.3% over the same quarter in the previous year. The company’s medical devices business grew by 5.9% to $6.97 billion in sales compared with the first quarter of 2021. Sales at J&J’s consumer health business, which it is spinning off into a separate publicly-traded company, declined 1.5% to $3.59 billion.

In pharmaceuticals, Wolk said recent prescriptions slowed in early January when the Covid omicron variant swept the U.S. but picked up in February and March. He said J&J’s medical devices business led the company’s growth with an uptick in general and advanced surgery and orthopedics. The company’s medical devices segment has struggled during Covid increases when elective procedures are delayed because hospitals are overwhelmed with sick patients with the virus.

About Us

We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.

Recent Posts

Transforming the delivery of Professional Services Worldwide |  Zain Ali

Manufacturers often struggle with generating accurate and timely quotes, delaying customer responses and risking profitability. Traditional quoting processes can take days or even weeks, while customers expect responses within 24 hours. Micro Estimating Systems addresses these challenges with advanced software that allows users to generate highly accurate quotes in minutes. By integrating with shop-specific data and automating feature recognition, their solutions ensure precision and speed, empowering manufacturers to make informed decisions and enhance their operational efficiency.

The must have Travel App after lockdown | Tiff Burns

Manufacturers often struggle with generating accurate and timely quotes, delaying customer responses and risking profitability. Traditional quoting processes can take days or even weeks, while customers expect responses within 24 hours. Micro Estimating Systems addresses these challenges with advanced software that allows users to generate highly accurate quotes in minutes. By integrating with shop-specific data and automating feature recognition, their solutions ensure precision and speed, empowering manufacturers to make informed decisions and enhance their operational efficiency.

The Technology Expert | Tarcisio Vergani

Manufacturers often struggle with generating accurate and timely quotes, delaying customer responses and risking profitability. Traditional quoting processes can take days or even weeks, while customers expect responses within 24 hours. Micro Estimating Systems addresses these challenges with advanced software that allows users to generate highly accurate quotes in minutes. By integrating with shop-specific data and automating feature recognition, their solutions ensure precision and speed, empowering manufacturers to make informed decisions and enhance their operational efficiency.

Perpetua Investment Group A Man of Action | Mehdi El Jazouli

Manufacturers often struggle with generating accurate and timely quotes, delaying customer responses and risking profitability. Traditional quoting processes can take days or even weeks, while customers expect responses within 24 hours. Micro Estimating Systems addresses these challenges with advanced software that allows users to generate highly accurate quotes in minutes. By integrating with shop-specific data and automating feature recognition, their solutions ensure precision and speed, empowering manufacturers to make informed decisions and enhance their operational efficiency.

J&J lowered its revenue and earnings expectations for 2022